

 Open access • Journal Article • DOI:10.3109/02656736.2013.821527

## Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: A review — [Source link](#)

Edouard AlphanDéry, Imène Chebbi, François Guyot, Mickaël Durand-Dubief

**Institutions:** Pierre-and-Marie-Curie University

**Published on:** 12 Nov 2013 - International Journal of Hyperthermia (Taylor & Francis)

**Topics:** Magnetotactic bacteria and Magnetosome

Related papers:

- [Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy.](#)
- [Learning from Nature to Improve the Heat Generation of Iron-Oxide Nanoparticles for Magnetic Hyperthermia Applications](#)
- [Preparation of chains of magnetosomes, isolated from Magnetospirillum magneticum strain AMB-1 magnetotactic bacteria, yielding efficient treatment of tumors using magnetic hyperthermia.](#)
- [Magnetosome formation in prokaryotes](#)
- [Heat Production by Bacterial Magnetosomes Exposed to an Oscillating Magnetic Field](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/use-of-bacterial-magnetosomes-in-the-magnetic-hyperthermia-27k0lfbxxh>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumors: A review.

Edouard Alphandéry<sup>+,-,\*</sup>, Imène Chebbi<sup>+</sup>, François Guyot<sup>-</sup>, Mickaël Durand-Dubief<sup>+</sup>

<sup>+</sup> Nanobacterie SARL, 36 boulevard Flandrin, 75016, Paris, France.

<sup>-</sup> IMPMC, UPMC, 4 place Jussieu, 75005, Paris, France.

\*Corresponding author: Edouard Alphandéry (edouardalphandery@hotmail.com)

1  
2  
3 *Introduction:*  
4

5  
6 Magnetic hyperthermia is a method used for treating cancers in which iron oxide nanoparticles are  
7 administered (or sent) to tumors and heated under the application of an alternating magnetic field.  
8

9  
10 The heat produced by the nanoparticles induces anti-tumor activity. To date, most nanoparticles  
11 tested pre-clinically, [1-3], and clinically, [4], were chemically synthesized, mainly in the form of  
12 superparamagnetic iron oxide nanoparticles (SPION). However, SPION possess a series of drawbacks,  
13 including a thermally unstable magnetic moment that yields non-optimized magnetic properties;  
14 they are small in size which usually result in the production of a small amount of heat under the  
15 application of an alternating magnetic field and they tend to aggregate which can cause toxicity *in*  
16 *vivo*. Such drawbacks can be avoided by using biologically synthesized nanoparticles, called  
17 magnetosomes, which are produced by several strains of a species of bacteria, called magnetotactic  
18 bacteria, MTB, [5]. Magnetosomes are large monodomain ferrimagnetic nanoparticles, which are  
19 composed of a core of crystallized maghemite or magnetite surrounded by biological material  
20 essentially made of lipids and proteins. They are usually arranged in chains and are used by MTB as a  
21 compass to navigate in the direction of the earth magnetic field. There are essentially two features  
22 that make the magnetosomes appealing for the magnetic hyperthermia treatment of tumors: (i) their  
23 large size and ferrimagnetic behavior enable the production of a large amount of heat when they are  
24 exposed to an alternating magnetic field and (ii) their arrangement in chains prevents aggregation,  
25 yields a high rate of cellular internalization and enables uniform heating throughout the tumor, [6, 7].  
26  
27

28  
29 Here, we review the most recent and significant results published in the field of MTB in particular  
30 data relating to the use of bacterial magnetosomes in magnetic hyperthermia for the treatment of  
31 tumors. We review different methods for cultivating MTB and preparing suspensions of bacterial  
32 magnetosomes. As well as the production of magnetosomes, we also review key data on the toxicity  
33 of the magnetosomes as well as their heating and anti-tumor efficiencies. The toxicity and efficiency  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

of magnetosomes needs to be understood and to measure the risk-benefit ratio, with which to evaluate their use in the magnetic hyperthermia treatment of tumors.

## 1. Culture of MTB and preparation of the magnetosomes

### 1.1 Culture of magnetotactic bacteria:

There are several species of MTB that can be cultivated including both marine and freshwater bacteria (MS-1, MV-1, MSR-1 and AMB-1). In this review, we describe the methods used for the growth of the most widely studied and commercially available strains, *Magnetospirillum Sp.* MSR-1 and AMB-1 MTB (MSR-1 DSMZ-6361 and AMB-1 ATCC-700264). The optimization of the growth of *Magnetospirillum gryphiswaldense* MSR-1 MTB has been described in a series of three successive publications, [8-10]. First, MSR-1 MTB were cultivated in growth medium containing magnesium sulfate ( $MgSO_4$ ), sodium thioglocate, yeast extracts, minerals, ferric citrate, ammonium chloride ( $NH_4Cl$ ) and sodium lactate in a 42 L fermentor, [8]. This medium was inoculated with 4.2 L of MSR-1 MTB suspension. During growth, the pH was maintained at 7 using fed-batch conditions in which a solution containing sodium lactate,  $NH_4Cl$  and ferric citrate was added to the growth medium. These conditions enabled maintenance of a sustainable growth rate for the bacteria. The concentration of dissolved oxygen (DO) in the growth medium, which is an important parameter that influences both the growth rate of the bacteria and the magnetosome production yield, was kept below 10% oxygen saturation to enhance the cell biomass. The production of magnetosomes was then triggered by reducing the DO concentration to 1% oxygen saturation. Such low DO values were obtained by progressively increasing the stir rate from 100 rpm up to 300 rpm during the growth of the bacteria, while sterile air was bubbled through the growth medium at a low speed of 0.3 L/min. These conditions allowed the synthesis of a high number of magnetosomes per bacterium (~ 25) and the production of a large percentage of magnetosomes containing cells (between 90 and 100 %). After 60 hours of growth, the magnetosome production yield and the magnetosome productivity for MSR-1

1  
2  
3 were 42 mg/L and 17 mg/L/day respectively. This growth protocol was further optimized by using a  
4  
5 different method for more accurate control of the percentage of oxygen contained within the  
6  
7 fermentor, [9]. This was achieved by changing both the stir rate and the air flow during the growth of  
8  
9 the bacteria. After 36 hours of bacterial growth, the magnetosome production yield a magnetosome  
10  
11 productivity increased to 83 mg/L and 55 mg/L/day respectively, [9]. A second improvement was  
12  
13 achieved by replacing the sources of carbon and nitrogen in the bacterial growth medium to avoid  
14  
15 the accumulation of sodium and chloride ions, which are toxic for non-marine species of MTB such as  
16  
17 MSR-1 and inhibit high cell concentrations, [10]. Under these conditions, after 36 hours of growth,  
18  
19 the magnetosome production yield and magnetosome productivity further increased to 168 mg/L  
20  
21 and 68 mg/L/day, respectively. Another method used to cultivate MSR-1 MTB, not involving fed-  
22  
23 batch conditions, yielded a rapid production of magnetosomes in 4 hours and a magnetosome  
24  
25 productivity of 6.3 mg/L/hour and 151/mg/L/day, [11]. This method has the advantage of being  
26  
27 simpler and therefore more practicable for the industrial production of MTB under good  
28  
29 manufacturing practice (GMP) conditions. For the growth of AMB-1 MTB, it has been shown that it is  
30  
31 possible to grow these bacteria in a large 1000 liters fermentor which can produce 2.6 g of  
32  
33 magnetosomes after 7 days, [12]. In this study, the growth medium was completely saturated with  
34  
35 nitrogen gas, [12]. As for MSR-1 MTB, AMB-1 MTB were also cultivated in fed-batch conditions.  
36  
37 These bacteria were grown in a 4 L fermentor in ATCC medium 1653 and maintained at pH 6.75 by  
38  
39 adding nitric acid solution. This enabled a magnetosome production yield of 4.5 mg/L, [13]. This  
40  
41 growth protocol was further optimized by changing the feeding solution and the source of iron, [14].  
42  
43 AMB-1 MTB were cultivated in a 10 L fermentor with a pH-stat system. The feeding solution  
44  
45 contained succinic acid, sodium nitrate, and nitric acid. Iron gallate and iron sulfate were the iron  
46  
47 sources found to give the most optimum yield of magnetosome production. The oxygen  
48  
49 concentration was maintained between 9 and 15% in the gas phase, which was found to be the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 optimum oxygen concentration for magnetosome production. Under these conditions, the  
4  
5 magnetosome production yield reached 15 mg/L, [14].  
6  
7

8 The optimizations of the growth conditions described above will enable industrial developments,  
9  
10 which require the production of a large quantity of magnetosomes. These large volumes can indeed  
11  
12 be obtained either by using a growth method that yields high level of magnetosomes via the  
13  
14 cultivation of MSR-1 MTB, [10], or by the culture of MTB in large volumes, [12]. In this regard, iron  
15  
16 chelating agents such as hemoglobin, EDTA and rhodamine, could be introduced into the bacterial  
17  
18 growth medium to enhance the growth rate of magnetotactic bacteria and to increase the  
19  
20 magnetosome production yield, [15]. For example, introducing 0.4  $\mu$ M of hemoglobin solution into  
21  
22 the growth medium of AMB-1 MTB, increased the quantity of magnetosomes produced by a factor of  
23  
24  $\sim 8$ , [15]. Finally, reasonably high magnetosome productivity of 6.3 mg/L/hour has been achieved  
25  
26 under batch conditions, which are more favorable in an industrial setting than fed-batched  
27  
28 conditions, [11].  
29  
30  
31

### 32 *1.2 Isolation of the magnetosomes from the magnetotactic bacteria:*

33

34  
35 There are two reasons why suspensions of MTB could not be used for magnetic hyperthermia  
36  
37 treatments of cancers: (i) the concentration of magnetosomes in a suspension of MTB is too low and  
38  
39 results in poor heating efficiency and thus absence of any anti-tumor activity, [6], and (ii) health and  
40  
41 safety issues preventing the administration of whole MTB into humans. To be used in cancer therapy,  
42  
43 the magnetosomes must therefore be isolated from the MTB. The methods used in the preparation  
44  
45 of these isolated magnetosomes are described below. To extract the magnetosomes from MTB, four  
46  
47 main techniques have been tested, which use sodium hydroxide (NaOH), sonication, a French press  
48  
49 or a pressure homogenizer to lyse the bacterial cells. The first tested method involved the mixing of  
50  
51 MSR-1 MTB with a 5 M NaOH solution for approximately 16 hours before their centrifugation for 10  
52  
53 hours at 8000 rpm to separate the magnetosomes from the debris of bacterial cells, [16]. This  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 seemed to have resulted in magnetosomes organized in chains, clumps and loops, [16]. The second  
4  
5 involved sonications at 300 W for 15 minutes, [17], 80 W for 10 minutes, [18], or 30 W for two hours,  
6  
7 [6], to lyse MSR-1, MS-1 and AMB-1 MTB, respectively. Using this method, the highest sonication  
8  
9 power led to the extraction of aggregated magnetosomes, [17], and the lowest sonication power  
10  
11 gave well dispersed chains of magnetosomes, [6, 18]. The third test, involving the passing of  
12  
13 suspensions of MTB two to three times through a French press at a pressure of 1000-20 000 lb/in<sup>2</sup> to  
14  
15 lyse AMB-1, [19], and MSR-1, [20, 21], MTB resulted in aggregated magnetosomes [20, 21]. Finally, a  
16  
17 pressure homogenizer has also been used to lyse MSR-1 MTB, [22, 23] at a pressure of 9000-18000  
18  
19 lb/in<sup>2</sup>, [23]. While this method does preserve the magnetosome membrane, [23], on which  
20  
21 magnetosome organization depends, [24], only a few transmission electron microscopic images of  
22  
23 the magnetosomes isolated using this method have been published making it difficult to confirm  
24  
25 with certainty the magnetosome organization, [22, 23]. The technique used to lyse the cells, which  
26  
27 produces different levels of bacterial cell disruption, does affect the magnetosome organization, [24].  
28  
29  
30

### 31 32 *1.3 Purification of the suspension of magnetosomes:*

33  
34 Following extraction of the magnetosomes from whole MTB, several different methods have been  
35  
36 suggested for their purification. One of the most comprehensive methods described involved a  
37  
38 system of magnetic isolation followed by low power ultrasonication and treatment with urea;  
39  
40 treatment with proteinase K to remove adsorbed and surface proteins and with electro-elution to  
41  
42 remove nucleic acids, [22]. The magnetosomes were then lyophilized and sterilized with gamma rays,  
43  
44 [22]. Other techniques have used phenylmethylsulfonyl fluoride to inhibit the activity of the  
45  
46 protease; a MACS magnetic column to wash the suspension of magnetosomes with Hepes buffer,  
47  
48 [25], and a treatment with 5 µg/ml of DNase I for two hours to remove DNA, [26]. To examine if the  
49  
50 purification was successful, the suspension of magnetosomes was centrifuged and the absorption of  
51  
52 the supernatant was measured at 280 nm. Therefore, the amount of biological material remaining in  
53  
54 the supernatant could be quantified. A successful purification method would lead to a only a small  
55  
56  
57  
58  
59  
60

1  
2  
3 quantity of biological material remaining in the supernatant and therefore a low absorbance, [27].  
4  
5 The percentage of magnetosomes obtained from 1 g of cells depends on the extraction and  
6  
7 purification methods used and ranges between 0.6 % and 4 %, [20, 25, 27].  
8  
9

#### 10 *1.4 Characterization of the suspension of magnetosomes:*

11

12  
13 Characterization of the magnetosome suspension is another important aspect to be considered.  
14  
15 Indeed, before administering a suspension of magnetosomes to humans, its full characterization is  
16  
17 first required. The biological material surrounding magnetosomes, which is essentially made of fatty  
18  
19 acids, phospholipids and proteins, has been mainly characterized using chromatography, infra-red  
20  
21 spectroscopy, SDS-page and mass spectroscopy. Previous studies have shown that around 18  
22  
23 proteins were surround the magnetosomes in the MSR-1 species, representing 4% of the total  
24  
25 weight, [25]. Lipids represent a higher percentage of the total weight of the magnetosomes, (~ 17%),  
26  
27 consisting of 1.4% of neutral lipids and free fatty acids, 5.1% of glycolipids, sulfolipids and  
28  
29 phosphatides and 10.5% of phospholipids, [27]. The concentration of the magnetosome suspension,  
30  
31 which needs to be known before administration, has been estimated previously using optical density  
32  
33 at 650 nm, [19], or 480 nm, [6], and by a using a destructive assay that measures the iron  
34  
35 concentration in the suspension, [6]. Transmission electron microscopy has been used to measure  
36  
37 the sizes of the magnetosome cores, which are made of crystallized iron oxide and range between 20  
38  
39 and 120 nm, [5]. For AMB-1 and MSR-1 species, the sizes of most the magnetosomes range between  
40  
41 30 and 50 nm and the magnetosomes usually possess a cubooctahedral geometry. The composition  
42  
43 of the magnetosome core has been reported to be either magnetite, maghemite or intermediate  
44  
45 between magnetite and maghemite depending on the level of exposure of the magnetosomes to  
46  
47 oxygen, [28]. Magnetic measurements were used to distinguish between these two compositions by  
48  
49 measuring the presence (or not) of the Verwey transition, which revealed the presence (or not) of  
50  
51 magnetite in the magnetosome core, [28].  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 2. *Magnetosome toxicity and biodistribution*  
4  
5

6 2.1 *Cytotoxicity of the magnetosomes:*  
7

8 Cytotoxicity, acute toxicity and immunotoxicity of the bacterial magnetosomes have been assessed  
9 and the magnetosome biodistribution has been studied following both intravenous and intratumoral  
10 routes of administration. These studies were carried out using bacterial magnetosomes isolated from  
11 MTB and then purified.  
12  
13  
14  
15  
16

17  
18 2.2 *Acute toxicity of the magnetosomes:*  
19

20 Despite their bacterial origin, suspensions of magnetosomes have shown little cytotoxic effects on  
21 mouse fibroblast, H22, HL60 and EMT-6 cells, (29). It was found that 9 µg/mL of bacterial  
22 magnetosomes was not toxic for H22, HL60 and EMT-6 cells. For mouse fibroblast cells incubated in  
23 the presence of various concentrations of suspensions of bacterial magnetosomes, no cytotoxicity  
24 was observed at a magnetosome concentration below 1.3 mg/mL, [21]. Bacterial magnetosomes  
25 incubated with MDA-MB-231 cells did not induce cell death or a significant cell inhibition at a  
26 magnetosome concentration below 125 µg/mL, (6).  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The acute toxicity of magnetosomes has also been studied in mice and rats. Suspensions of  
37 magnetosomes at doses of 270, 360 or 480 mg/kg were injected intravenously. All mice survived  
38 except those treated with the highest dose of magnetosomes, i.e. ~ 0.5% of body weight. In  
39 comparison, the mice treated with standard chemical SPION began to die after a lower dose of  
40 nanoparticles injected at 135 mg/kg, [30]. In another study, suspensions of magnetosomes were  
41 administered to rats intravenously. The rats survived when less than 82 mg/kg of magnetosomes  
42 were administered, [29]. However, for the rats that died in this study (when administered with more  
43 than 82 mg/kg of magnetosomes), it was reported that their death may have been accidental, due to  
44 bacterial infection and not to the administration of the magnetosome suspension. Histological  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 analysis of the main organs (heart, liver, spleen, lung, kidney, brain, intestines, lymph glands and  
4  
5 thymus) indicated the absence of hemorrhage, inflammation and hyperemia in the rats treated with  
6  
7 less than 82 mg/kg of bacterial magnetosomes.  
8  
9

### 10 *2.3 Immuno-toxicity of the magnetosomes:*

11  
12  
13 The toxicity of magnetosomes is not likely to be due to iron chemical toxicity since  $\text{Fe}_3\text{O}_4$  is relatively  
14  
15 insoluble. While dissolved iron ions may be toxic due to a Fenton reaction, which leads to the  
16  
17 formation of hydroxyl radicals that are strong oxidants,  $\text{Fe}_3\text{O}_4$  does not produce the same toxic  
18  
19 effect. Indeed, the magnetosomes are not reported to trigger the Fenton reaction. They even seem  
20  
21 to produce the opposite effect by scavenging reactive oxygen species, [31]. The toxicity of  
22  
23 magnetosomes could also be due to their nanometric sizes that might result in embolism, blood clot,  
24  
25 cell toxicity or acute toxicity as described above. On the other hand, it could also arise from the  
26  
27 magnetosome biological impurities, such as the proteins, the nucleic acids and the  
28  
29 lipopolysaccharides (LPS) surrounding the magnetosomes that could lead to potential  
30  
31 immunotoxicity, [32]. The latter was studied by administering a 1 mg suspension of magnetosomes  
32  
33 into the ears of rabbits and then monitoring body temperatures after the injection, [29]. Body  
34  
35 temperature did not increase suggesting the absence of a pyrogenic effect. Moreover, intravenous  
36  
37 administration of 40 mg/kg magnetosome suspension into rats revealed no difference in the number  
38  
39 of white blood cells and lymphocytes to those in untreated rats. The stimulation index of lymphocyte  
40  
41 cells, which is the ratio between the number of proliferating T lymphocytes present in a lymphocyte  
42  
43 culture after exposure to antigen to the total number of cells, was also measured for the rats treated  
44  
45 (or untreated) with an intravenous administration of a suspension of bacterial magnetosomes using  
46  
47 LPS as antigens. No difference was observed in the stimulating index between the treated and  
48  
49 untreated rats indicating the absence of immunotoxicity induced by the intravenous injection of 40  
50  
51 mg/kg of bacterial magnetosomes, [29]. Together, these results indicate that if purified correctly, the  
52  
53 magnetosomes do not induce side effects and are of low toxicity.  
54  
55  
56  
57  
58  
59  
60

#### 2.4 Magnetosome biodistribution:

Studies have also been carried out in mice and rats to investigate the biodistribution of magnetosomes following either an intravenous or an intratumoral route of administration. Their aims were to examine the possible degradation of the magnetosomes and to determine the elimination pathways. First studied was the potential decomposition of magnetosomes by lysosomes, known to degrade nanoparticles. For this, a suspension of magnetosomes isolated from MTB was mixed with crude protease from bovine pancreas that simulates intracellular lysosomal conditions, [26]. The magnetosomes appeared to be degraded after 28 days, suggesting that lysosomes are indeed able to degrade magnetosomes, [33]. The decomposition of magnetosomes by lysosomes was further confirmed by two experimental results. Firstly, suspensions of bacterial magnetosomes were administered to rats, [34], or mice, [23, 33], and their localization was determined by fluorescence microscopy, [23], or histological analysis of the main organs, [33, 34], one to fourteen days following administration. Magnetosomes were found in the liver [33, 34], spleen, [33], and lungs, [23], where they were located inside lysosomes in a partly degraded state. In these studies, the magnetosomes that ended up in the liver and spleen were digested by lysosomes, [33, 34]. Secondly, another study showed that three days following intravenous injection the magnetosomes were neither found in the feces nor in the urine, [34]. These results seem to indicate that the magnetosomes were degraded by the mice or rats. The hypothesis proposed in light of these results was that the reticuloendothelial system, composed of liver and spleen macrophages, removes magnetosomes from the bloodstream, [33]. Other studies, however, have found magnetosomes in the feces of mice following both intratumoral and intravenous routes of administrations, [6, 32]. Taken together, these results suggest that a portion of the bacterial magnetosomes is probably degraded while another portion is eliminated in the feces. Biodistribution studies of chemically synthesized nanoparticles revealed different features. For example, long-term follow up over a period of 6 months of chemically synthesized nanoparticles injected intravenously showed that these nanoparticles were metabolized in the organ's parenchyma

1  
2  
3 with metal ions leaking from the core material, [35]. However, there are still too few results  
4  
5 published on the magnetosome biodistribution to be able to compare in details the biodistribution of  
6  
7 the magnetosomes with that of chemically synthesized nanoparticles. Moreover, further studies are  
8  
9 necessary to determine more precisely the elimination and degradation pathways of bacterial  
10  
11 magnetosomes and to examine whether or not the magnetosomes are metabolized.  
12

### 13 14 3. *Magnetic hyperthermia treatment of tumors with magnetosomes:*

#### 15 16 17 3.1 *Heating properties of the magnetosomes:*

18  
19  
20 Bacterial magnetosomes are good candidates to carry out magnetic hyperthermia since they produce  
21  
22 a large amount of heat when exposed to an alternating magnetic field. In this review, we report  
23  
24 values of magnetosome losses per cycle as a measurement of the amount of heat produced by  
25  
26 magnetosomes. The magnetosome loss per cycle is defined as the magnetosome specific absorption  
27  
28 rate (SAR) divided by the frequency of oscillation of the alternating magnetic field, where the SAR is  
29  
30 usually estimated using the formula  $SAR = \rho_s C_s (\Delta T / \delta t) / C_{Fe}$ , where  $\rho_s$ ,  $C_s$  and  $C_{Fe}$  are the density,  
31  
32 calorific capacity and iron concentration of the sample respectively and  $\Delta T / \delta t$  is the slope of the  
33  
34 variation in temperature with time estimated at the beginning of the heat treatment, [36]. Using loss  
35  
36 per cycle is convenient since it enables comparison between SAR obtained for different alternating  
37  
38 magnetic field frequencies. The production of a large amount of heat by the magnetosomes is due to  
39  
40 their large sizes and ferrimagnetic behavior at physiological temperatures. Indeed, since the  
41  
42 magnetosomes are monodomain, ferrimagnetic and of cubic shape, the amount of heat that they  
43  
44 produce is proportional to their sizes. In addition, due to their thermally stable magnetic moment,  
45  
46 the magnetosomes produce a larger amount of heat than the smaller superparamagnetic chemically  
47  
48 synthesized nanoparticles. These behaviors have been shown both experimentally and theoretically,  
49  
50 [36-42]. For suspensions of magnetosomes exposed to a magnetic field of 6.2 mT, losses per cycles of  
51  
52 0.1-0.2 J/Kg were reported, [36-40]. When the strength of the magnetic field was increased to 12 mT,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the losses per cycles increased to 0.5-1 J/Kg (33, 37-39), showing that the magnetosome loss per  
4 cycle strongly increases with increasing magnetic field strength. By comparison with chemically  
5 synthesized nanoparticles, these losses per cycle are considerably larger at magnetic field strengths  
6 below 10 mT; and either equivalent, [40], or larger at magnetic field strengths above 10 mT, [41]. The  
7 heating mechanisms of bacterial magnetosomes have also been studied. Three different types of  
8 sample were prepared containing whole MTB, chains of magnetosomes extracted from AMB-1 MTB  
9 or individual magnetosomes detached from the chains by heat and SDS treatments, [41]. Figure 1  
10 shows transmission electron microscopy images of whole MTB (Figure 1(a)), chains of magnetosomes  
11 extracted from MTB (Figure 1(b)) and individual magnetosomes (Figure 1(c)). When suspensions of  
12 whole AMB-1 MTB were mixed with water and exposed to an alternating magnetic field frequency of  
13 108 KHz and strength of 23 to 88 mT, the losses per cycle ranged between 1.1 and 8 J/Kg<sub>Fe</sub> and the  
14 heat released by the magnetosomes was found to mainly arise from the inversion of the  
15 magnetosome magnetic moment under the application of an alternating magnetic field (magnetic  
16 viscosity). Indeed, it has been demonstrated that the contribution of the rotation of the whole  
17 bacteria to the production of heat was negligible, [41]. When the magnetosomes were extracted  
18 from whole MTB either as chains or individual nanoparticles, the heat released by the magnetosomes  
19 was reported to arise both from the inversion of the magnetosome magnetic moment (magnetic  
20 viscosity) and from the magnetosome rotation (hydrodynamic viscous coupling of the medium).  
21 Consequently, under the application of the same magnetic field strengths, the losses per cycle  
22 increased considerably to 5-11 J/Kg<sub>Fe</sub> compared with the values obtained using whole bacteria. It was  
23 not possible to determine from this study alone if the magnetosome chains or the individual  
24 magnetosomes would be the best candidate to carry out magnetic hyperthermia treatment of  
25 tumors since both types of magnetosomes led to high heating efficiencies. The influence on the  
26 heating properties of the magnetosome size and magnetosome magnetic anisotropy has also been  
27 studied, [15, 30]. To increase the magnetosome magnetic anisotropy, a 2 μM solution of cobalt  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 quinate was introduced in the bacterial growth medium resulting in an increase in the  
4  
5 magnetocrystalline anisotropy constant by a factor of  $\sim 9$  from  $K_{\text{eff}} = 12 \text{ KJ/m}^3$  in the absence of cobalt  
6  
7 up to  $K_{\text{eff}} = 104 \text{ KJ/m}^3$  in the presence of cobalt quinate, [30]. This increase in magnetosome  
8  
9 magnetic anisotropy resulted in an increase in the SAR, [30]. To increase magnetosome sizes, iron  
10  
11 chelating agents such as EDTA and rhodamine B were introduced in the bacterial growth medium.  
12  
13 This resulted in an increase of the mean magnetosome sizes from 42.5 nm in the absence of iron  
14  
15 chelating agents up to 60-65 nm in the presence of rhodamine B or EDTA that produced an  
16  
17 enhancement of the magnetosome heating properties, [15].  
18  
19

### 20 21 3.2 *Antitumor activity of the magnetosomes:*

22  
23 Although bacterial magnetosomes belong to a type of iron oxide nanoparticles that produces a large  
24  
25 amount of heat when exposed to an alternating magnetic field, [6, 36-41], the anti-tumor activity  
26  
27 resulting from a magnetic hyperthermia treatment has to our knowledge only been evaluated in two  
28  
29 studies, [6, 33]. When MCF-7 tumor cells were mixed with bacterial magnetosomes and heated  
30  
31 under the application of an alternating magnetic field to reach a temperature of 47 °C, 80% of the  
32  
33 cell proliferation was inhibited, [33]. It was also mentioned in this study that a temperature of 47 °C  
34  
35 inhibited more MCF-7 tumor cells than normal L929 cells. This result further supports the safety of  
36  
37 the treatment. Indeed, it suggests that if during the course of a magnetic hyperthermia treatment  
38  
39 healthy tissues are heated by mistake, the heat would be less damaging to healthy tissues than to  
40  
41 tumor tissues. MDA-MB-231 tumor cells were also incubated with a suspension of magnetosomes  
42  
43 and exposed to an alternating magnetic field under various conditions, [6]. The percentage of cell  
44  
45 death and cell inhibition increased with increasing concentrations of magnetosomes, increasing  
46  
47 incubation times, magnetic field strength and the number of times that the heat treatment was  
48  
49 repeated. This suggests that an efficient treatment can be achieved provided optimum values of  
50  
51 these four parameters are chosen.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We performed a proof of concept study for the therapy on breast tumors xeno-grafted under the  
4 skin of mice, [6]. Four different types of suspensions were tested containing whole MTB (Figure 1(a)),  
5 magnetosomes organized in chains (Figure 1(b)), individual magnetosomes (Figure 1(c)) and SPION.  
6  
7 Each suspension contained 10 mg/mL of iron oxide and 100  $\mu$ L of each suspension was administered  
8  
9 with a syringe into the center of the xeno-grafted breast tumors ( $\sim 100 \text{ mm}^3$  in size) The mice were  
10  
11 then exposed three times during twenty minutes to an alternating magnetic field strength of 40 mT  
12  
13 and frequency of 198 kHz. The schematic diagram in Figure 2(a) shows the set-up used for the  
14  
15 treatment using an induction system that generates an alternating magnetic field. The treatments,  
16  
17 which used the suspensions of whole MTB, individual magnetosomes and SPION, were inefficient and  
18  
19 were unable to stop the growth of the tumor. In contrast, when the heat treatment was carried out  
20  
21 using suspensions of chains of magnetosomes, the tumors in several mice disappeared. Figure 2(b)  
22  
23 shows a mouse during the treatment. Typical temperatures reached during the treatment with the  
24  
25 chains of magnetosomes were around 45-46  $^{\circ}\text{C}$  as estimated by infra-red measurements (Figure  
26  
27 2(b)). Thirty days following the treatment, the tumor had disappeared in the mouse treated with the  
28  
29 chains of magnetosomes (Figure 2(c)), while it was still located at the skin surface of the mice treated  
30  
31 with individual magnetosomes (Figure 2(d)) or SPION (Figure 2(e)). We can conclude from these  
32  
33 results that the efficiency of the bacterial magnetosomes is not only due to their large sizes but also  
34  
35 comes from their arrangement in chains. When the magnetosomes are organized in chains, they are  
36  
37 less prone to aggregation. Indeed, several chains of magnetosomes interact in a head to tail manner  
38  
39 in such a way that they form a longer chain. This behavior can clearly be observed in Figure 1. In  
40  
41 Figure 1(a), the chains of magnetosomes contained inside the magnetotactic bacterium are short,  
42  
43 containing  $\sim 10$  magnetosomes. After extraction from the magnetotactic bacteria, the chains of  
44  
45 magnetosomes are much longer, containing typically more than  $\sim 20$  magnetosomes (Figure 1(b)).  
46  
47 By contrast, when the magnetosomes are not organized in chains, they tend to form compactly  
48  
49 aggregated assemblies of individual magnetosomes. This has been shown by studying the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 organization of individual magnetosomes obtained by heat and SDS treatments, [6], or by genetic  
4  
5 manipulations of magnetotactic bacteria that led to the removal of the filament binding the  
6  
7 magnetosomes together in a chain inside MTB, [43].  
8  
9

10 We then examined the impact of the organization in chains of the magnetosomes on the heating and  
11  
12 distribution uniformity as well as on cellular internalization, [6,7]. The heating uniformity was studied  
13  
14 by infrared measurements and histological analysis, which showed a more uniform heating and  
15  
16 distribution throughout the tumor for the chains of magnetosomes than for the individual  
17  
18 magnetosomes. The internalization of the chains of magnetosomes inside the cells was observed by  
19  
20 two types of measurements. The chains of magnetosomes were mixed with MDA-MB-231 cells and  
21  
22 exposed to an alternating magnetic field which resulted in the formation of magnetic cells 5 minutes  
23  
24 after the beginning of the treatment. Figure 3(a) shows an eppendorf containing MDA-MB-231 cells  
25  
26 mixed with chains of magnetosomes being exposed to the alternating magnetic field. Before the  
27  
28 application of the alternating magnetic field, Figure 3(b) shows that the cells are not attracted by a  
29  
30 magnet positioned next to the eppendorf and are therefore non-magnetic. Therefore, only a small  
31  
32 black spot located next to the magnet is visible corresponding to magnetosomes without cells being  
33  
34 attracted by the magnet. By contrast, after the application of the alternating magnetic field, as  
35  
36 shown in Figure 3(c), a large dark spot appeared next to the magnet relating to the magnetic cells  
37  
38 attracted by the magnet. MDA-MB-231 cells were also incubated in the presence of the chains of  
39  
40 magnetosomes for 1 minute and 24 hours using Prussian blue, which reveals the presence of iron.  
41  
42 Figures 3(d) shows the absence of magnetosome internalization after one minute and an efficient  
43  
44 internalization after 24 hours of incubation (Figure 3(e)). These results indicate that both the  
45  
46 application of the alternating magnetic field and the incubation of magnetosomes for a long period  
47  
48 of time cause high cellular internalization. Histological analysis of the tumor tissues revealed the  
49  
50 presence of aggregated magnetosomes in the mice treated with individual magnetosomes (Figure  
51  
52 4(a)) whereas magnetosomes internalized within the cells were observed only in the mice treated  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 with suspensions of chains of magnetosomes, (Figures 4(b) and 4(c)). We concluded that uniform  
4 heating, uniform magnetosome distribution as well as effective cellular internalization were  
5 responsible for the high anti-tumoral efficiency observed with the chains of magnetosomes. The  
6 large sizes of the magnetosomes, which yield high values of the SAR, are not sufficient to produce  
7 high anti-tumor activity. The distribution of the magnetosomes in the tumor is another key  
8 parameter that influences the efficiency of the treatment.  
9  
10  
11  
12  
13  
14  
15

### 16 3.3 *Comparison between the chains of magnetosomes and the individual magnetosomes:*

17  
18  
19 Chains of magnetosomes have been defined as assemblies of magnetosomes in which the  
20 crystallographic directions of most of the magnetosomes are aligned in the direction of the chain  
21 elongation, [44]. Individual magnetosomes are assemblies of magnetosomes in which such alignment  
22 does not take place. The chains of magnetosomes differ from the individual magnetosomes by their  
23 coating. Using infra-red measurements, it has been shown that the chains of magnetosomes were  
24 coated by a mixture of lipids and proteins whereas the individual magnetosomes were only coated by  
25 lipids, [7]. Most probably due to different coatings, the chains of magnetosomes were found to have  
26 a zeta potential (-22 mV at pH 7), which differs from that of the individual magnetosomes (+ 10 mV at  
27 pH 7), [7]. The magnetic anisotropy of these two types of magnetosomes was studied by depositing a  
28 suspension of these two types of magnetosomes on a substrate under the application of a magnetic  
29 field, [45]. Magnetic anisotropy was evaluated by measuring the hysteresis loops of these two types  
30 of magnetosomes for a magnetic field applied either parallel or perpendicular to the direction of the  
31 alignment and by measuring the difference in coercivity and remanent magnetization between these  
32 two field configurations. A larger magnetic anisotropy was found for the chains of magnetosomes  
33 than for the individual magnetosomes. This comes from the better alignment of the easy axes in  
34 chains of magnetosomes than in individual magnetosomes, [45]. The larger magnetic anisotropy of  
35 the chains of magnetosomes compared with that of the individual magnetosomes could be another  
36 factor responsible for their lower tendency to aggregate. The chains of magnetosomes possess  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 advantageous properties for medical applications due to their low level aggregation. Such property  
4  
5 results in high cellular internalization and in uniform tumor distribution. It makes the chains leave the  
6  
7 tumor more rapidly than the individual magnetosomes or chemically synthesized nanoparticles. It  
8  
9 also results in a percentage of chains eliminated in the feces following intra-tumoral administration,  
10  
11 which is larger than that obtained with individual magnetosomes, [6].  
12

13  
14 *Conclusion:*

15  
16  
17 In conclusion, we have reviewed the most recent data published on the use of magnetosomes for  
18  
19 magnetic hyperthermia treatment of tumors. Studies report that it is possible to produce  
20  
21 magnetosomes in large quantity (150 mg/liter/day) and to purify the magnetosomes in such a way  
22  
23 that cytotoxicity is avoided. The acute toxicity of the magnetosomes was found to be low with rats  
24  
25 surviving up to a quantity of magnetosomes administered of 480 mg per Kg of animal. Suspensions of  
26  
27 magnetosomes heated under the application of an alternating magnetic field yield high loss power  
28  
29 per cycle of 5-11 J/Kg<sub>Fe</sub>, suggesting that the magnetosomes are good candidates for magnetic  
30  
31 hyperthermia treatments of tumors. Moreover, a proof of concept of a therapy using bacterial  
32  
33 magnetosomes as heating sources has been carried out on breast tumors xeno-grafted under the  
34  
35 skin of mice. It has revealed that it was possible to completely eradicate the xeno-grafted tumors  
36  
37 using this technique. Finally, two different types of magnetosomes have been studied, those  
38  
39 organized in chains, which possess cristallographic directions aligned in the direction of the chain  
40  
41 elongation and those organized as individual magnetosomes, which do not possess such alignment of  
42  
43 their cristallographic directions. It has been shown that the chains of magnetosomes produce the  
44  
45 best therapeutic results, mainly because of their low level of aggregation, which results in high  
46  
47 cellular internalization and uniform distribution throughout the tumor.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURES:

Figure 1: Transmission electron microscopy images of whole MTB, (a), chains of magnetosomes isolated from MTB, (b), and individual magnetosomes detached from the magnetosome chains by a heat and SDS treatment, (c).

Figure 2: (a) The set-up used to carry out the treatment of the mice by positioning the mice inside the copper coil and by applying an alternating magnetic field. (b) The measurement of the temperature during the treatment. Photographs of the mice treated with a suspension containing chains of magnetosomes, (c), individual magnetosomes, (d), or superparamagnetic iron oxide nanoparticles (SPION), (e).

Figure 3: (a) The set-up used to expose a suspension containing chains of magnetosomes mixed with MDA-MB-231 cells to an alternating magnetic field of average magnetic field strength of  $\sim 20$  mT and frequency of 198 kHz. A photograph showing this suspension placed next to a magnet before the application of the alternating magnetic field, (b), or after the application of the alternating magnetic field during 5 minutes, (c). Micrographs of MDA-MB-231 cells incubated with a suspension containing chains of magnetosomes during three minutes, (d), or 24 hours, (e).

Figure 4: Micrograph of a tumor tissue collected after the administration of the bacterial magnetosomes and three applications of an alternating magnetic field of average strength (20 mT) and frequency of 198 kHz for 20 minutes. The bacterial magnetosomes administered were individual magnetosomes, (a), or chains of magnetosomes, (b), (c). (c) is an enlargement of (b) and shows bacterial magnetosomes internalized within tumor cells.

## REFERENCES:

1. Jordan A, Scholz R, Maier-Hauff K, K.H. Van Landeghem F, Waldoedner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R, The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma, *Journal of NeuroOncology* 2006; 78: 7-14.
2. Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T, Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma, *Cancer Science* 2003; 94: 308-313.
3. Zhao Q, Wang L, Cheng R, Mao L, Arnold R D, Howerth E W, Chen Z G, Platt S, Magnetic Nanoparticle-Based Hyperthermia for Head and Neck Cancer in Mouse Models, *Theranostics* 2012; 2: 113-121.
4. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A, Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme, *Journal of Neurooncology* 2011; 103: 317-324.
5. Bazylnski D A, Frankel R B, Magnetosome formation in prokaryotes, *Nature Reviews Microbiology* 2004; 2: 217-230.
6. Alphandéry E, Faure S, Seksek O, Guyot F, Chebbi I, Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy, *ACSNano* 2011; 5: 6279-62296.
7. Alphandéry E, Guyot F, Chebbi I, Preparation of chains of magnetosomes, isolated from *Magnetospirillum magneticum* AMB-1 magnetotactic bacteria, yielding efficient treatment of

- 1  
2  
3 tumors using magnetic hyperthermia, International Journal of hyperthermia 2012; 434: 444-  
4  
5 452.  
6  
7
- 8 8. Sun J-B, Zhao F, Tang T, Jiang W, Tian J-S, Li J-L, High-yield growth and magnetosome  
9 formation by *Magnetospirillum gryphiswaldense* MSR-1 in an oxygen-controlled fermentor  
10 supplied solely with air, Appl. Microbiol. Biotechnol. 2008; 79: 389-397.  
11  
12
- 13 9. Liu Y, Li G R, Jiang W, Li Y, Li L J, Large-scale production of magnetosomes by chemostat  
14 culture of *Magnetospirillum gryphiswaldense* at high cell density, Microbial Cell Factories  
15 2010; 9:99.  
16  
17
- 18 10. Zhang Y, Zhang X, Jiang W, Li Y, Li J, Semicontinuous culture of *Magnetospirillum*  
19 *gryphiswaldense* MSR-1 cells in an autofermentor by nutrient-balanced and isosmotic  
20 feeding strategies, Applied and Environmental Microbiology 2011; 77: 5851-5856.  
21  
22
- 23 11. Heyen U, Schüler D, Growth and magnetosome formation by microaerophilic  
24 *Magnetospirillum* strains in an oxygen-controlled fermentor, Appl. Microbiol. Biotechnol.  
25 2003; 61: 536-544.  
26  
27
- 28 12. Matsunaga T, Tadokora F, Nakamura N, Mass culture of magnetic bacteria and their  
29 application to flow type immunoassays, IEEE Transactions on magnetic 1990; 26: 1557-1559.  
30  
31
- 32 13. Matsunaga T, Tsujimura N, Kamiya S, Enhancement of magnetic particle production by  
33 nitrate and succinate fed-batched culture of *Magnetospirillum* sp. AMB-1, Biotechnology  
34 techniques 1996; 10: 495-500.  
35  
36
- 37 14. Yang C-D, Takeyama H, Tanaka T, Matsunaga T, Effects of growth medium composition, iron  
38 sources and atmospheric oxygen concentrations on production of luciferase-bacterial  
39 magnetic particle complex by a recombinant *Magnetospirillum magneticum* AMB-1, Enzyme  
40 and Microbils Technology 2001 ; 29 : 13-19.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 15. Alphandéry E, Amor M, Guyot F, Chebbi I, The effects of iron-chelating agents on  
4  
5 Magnetospirillum magneticum strain AMB-1: stimulated growth and magnetosome  
6  
7 production and improved magnetosome heating properties, Appl. Microbiol. Biotechnol.  
8  
9 2012; 96: 663-670.  
10
- 11  
12 16. Philipse A P, Maas D, Magnetic colloids from magnetotactic bacteria: chain formation and  
13  
14 colloidal stability, Langmuir 2002; 18: 9977-9984.  
15  
16
- 17 17. Sun J-B, Duan J-H, Dai S-L, Ren J, Guo L, Jiang W, Li Y, Preparation and anti-tumor efficiency  
18  
19 evaluation of doxorubicin-loaded bacterial magnetosomes: magnetic nanoparticles as drug  
20  
21 carriers isolated from *Magnetospirillum gryphiswaldense*, Biotechnology and Bioengineering  
22  
23 2008; 101: 1313-1320.  
24  
25
- 26  
27 18. Taoka A, Asada R, Sasaki H, Anzawa K, Wu L F, Fukumori Y, Spatial localizations of Mam22  
28  
29 and Mam12 in the magnetosomes of *Magnetospirillum magnetotacticum*, Journal of  
30  
31 bacteriology 2006; 188: 3805-3812.  
32  
33
- 34 19. Matsunaga T, Maeda Y, Yoshino T, Takeyama H, Takahashi M, Ginya H, Aashina J, Tajima H,  
35  
36 Fully automated immunoassay for detection of prostate-specific antigen nano-magnetic  
37  
38 beads and micro-polystyrene bead composites, 'Beads on Beads', Analytica Chimica Acta  
39  
40 2007 ; 597 : 331-339.  
41  
42
- 43 20. Grünberg K, Müller E-C, Otto A, Reska R, Linder D, Kube M, Reinhardt R, Schüler D,  
44  
45 Biochemical and proteomic analysis of the magnetosome membrane in *Magnetospirillum*  
46  
47 *gryphiswaldense*, Applied and Environmental Microbiology 2004; 70: 1040-1050.  
48  
49
- 50  
51 21. Xiang L, Wei J, Jianbo S, Gulli W, Feng G, Ying L, Purified and sterilized magnetosomes from  
52  
53 *Magnetospirillum gryphiswaldense* MSR-1 were not toxic to mouse fibroblasts in vitro,  
54  
55 Letters in Applied Microbiology 2007; 45: 75-81.  
56  
57  
58  
59  
60

- 1  
2  
3 22. Guo F, Liu Y, Chen Y, Tang T, Jiang W, Li Y, Li J, A novel rapid and continuous procedure for  
4 large-scale purification of magnetosomes from *Magnetospirillum gryphiswaldense*, *Appl.*  
5 *Microbiol. Biotechnol.* 2011; 90: 1277-1283.  
6  
7  
8  
9  
10 23. Tang T, Zhang L, Gao R, Dai Y, Meng F, Li Y, Fluorescence imaging and targeted distribution of  
11 bacterial magnetic particles in nude mice, *Appl. Microbiol. Biotechnol.* 2012; 94: 495-503.  
12  
13  
14 24. Kobayashi A, Kirschvink J, Nash C Z, Kopp R E, Sauer D A, Bertani L E, Voorhout W F, Taguchi  
15 T, Experimental observation of magnetosome chain collapse in magnetotactic bacteria:  
16 Sedimentological paleomagnetic, and evolutionary implications, *Earth and Planetary Science*  
17 *Letters* 2006; 245: 538-550.  
18  
19  
20  
21  
22  
23 25. Grünberg K, Wawer C, Tebo B M, Schüler D, A large gene cluster encoding several  
24 magnetosome proteins is conserved in different species of magnetotactic bacteria, *Applied*  
25 *and Environmental Microbiology* 2001; 67: 4573-4582.  
26  
27  
28  
29  
30  
31 26. Sun J-B, Duan J-H, Dai S-L, Ren J, Zhang Y-D, Tian J-S, Li Y, In vitro and in vivo antitumor  
32 effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: The  
33 magnetic bio-nanoparticles as drug carriers, *Cancer letters* 2007; 258: 109-117.  
34  
35  
36  
37  
38  
39 27. Gorby Y A, Beveridge T J, Blakemore R P, Characterization of the bacterial magnetosome  
40 membrane, *Journal of bacteriology* 1988; 170: 834-841.  
41  
42  
43  
44 28. Alphandéry E, Ngo A T, Lefèvre C, Lisiecki I, Wu L F, Pileni M P, Difference between the  
45 magnetic properties of the magnetotactic bacteria and those of the extracted chains of  
46 magnetosomes: Influence of the distance between the chains of magnetosomes, *J. Phys.*  
47 *Chem C* 2008; 112: 12304-12309.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 29. Sun J, Tang T, Duan J, Xu P-X, Wang Z, Zhang Y, Wu L, Li Y, Biocompatibility of bacterial  
4 magnetosomes: Acute toxicity, immunotoxicity and cytotoxicity, *Nanotoxicology* 2010; 4:  
5 271-283.  
6  
7  
8  
9  
10 30. Alphanđery E, Carvollo C, Menguy N, Chebbi I, Chains of cobalt doped magnetosomes  
11 extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field  
12 cancer therapy, *Journal of physical Chemistry C* 2011; 115: 11920-11924.  
13  
14  
15  
16  
17 31. Guo F F, Yang W, Jiang W, Geng S, Peng T, Li J L, Magnetosomes eliminate intracellular  
18 reactive oxygen species in *Magnetospirillum gryphiswaldense* MSR-1, *Environmental*  
19 *Microbiology* 2012; 14: 1722-1729.  
20  
21  
22  
23  
24  
25 32. Unpublished data. Suspensions magnetosomes were administered intravenously to mice.  
26 They were observed in the feces of these mice collected after the administration by  
27 transmission electron microscopy.  
28  
29  
30  
31  
32 33. Liu R-T, Liu J, Tong J-Q, Tang T, Kong W-C, Wang X-W, Li Y, Tang J-T, Heating effect and  
33 biocompatibility of bacterial magnetosomes as potential materials used in magnetic fluid  
34 hyperthermia, *Progress in Natural Science: Materials International* 2012; 22: 31-39.  
35  
36  
37  
38  
39 34. Sun J-B, Wang Z-L, Duan J-H, Ren J, Yang X-D, Dai S-L, Li Y, Targeted distribution of bacterial  
40 magnetosomes isolated from *Magnetospirillum gryphiswaldense* MSR-1 in healthy Sprague-  
41 Dawley rats, *Journal of Nanoscience and Nanotechnology* 2009; 9: 1881-1885.  
42  
43  
44  
45  
46 35. Lacava L M, Garcia V A P, Kückelhaus S, Azevedo R B, Sadeghiani N, Buske N et al, Long-term  
47 retention of dextran-coated magnetite nanoparticles in the liver and spleen, *J. Magn. Magn.*  
48 *Mater.* 2004; 272: 2434-2435.  
49  
50  
51  
52  
53 36. Timko M, Dzarova A, Skumiel A, Jozefcak A, Hornowski T, Gojzewski H, Zavisova V, Koneracka  
54 M, Sprincova A, Strebak O, Kopcansky P, Tomasovicova N, Magnetic properties and heating  
55  
56  
57  
58  
59  
60



- 1  
2  
3 effect in bacterial magnetic nanoparticles, Journal of Magnetism and Magnetic Materials  
4  
5 2009; 321: 1521-1524.  
6  
7
- 8 37. Timko M, Molcan M, Hashim A, Skumiel A, Muller M, Gojzewski H, Jozefcak A, Kovac J, Rajnak  
9  
10 M, Makowski M, Kopcansky P, Hyperthermic effect in suspension of magnetosomes prepared  
11  
12 by various methods, IEE Transactions on magnetic 2013; 49: 250-254.  
13  
14
- 15 38. Hergt R, Dutz S, Roder M, Effects of size distribution on hysteresis losses of magnetic  
16  
17 nanoparticles for hyperthermia, Journal of Physics condensed matter 2008; 20: 385214.  
18  
19
- 20 39. Hergt R, Hiergeist R, Zeisberger M, Schüler D, Heyen U, Hilger I, Kaiser W, Magnetic  
21  
22 properties of bacterial magnetosomes as potential diagnostic and therapeutic tools, Journal  
23  
24 of Magnetism and magnetic materials 2005; 293: 80-86.  
25  
26
- 27 40. Dutz S, Hergt R, Mürbe J, Müller R, Zeisberger M, Andrä W, Töpfer J, Bellemann M E,  
28  
29 Hysteresis losses of magnetic nanoparticle powders in the single domain size range, Journal  
30  
31 of Magnetism and magnetic materials 2007; 308: 305-312.  
32  
33
- 34 41. Alphandéry E, Faure S, Raison L, Duguet E, Howse P A, Bazylinski D A, Heat production by  
35  
36 bacterial magnetosomes exposed to an oscillating magnetic field, Journal of physical  
37  
38 chemistry C 2011; 115: 18-22.  
39  
40
- 41 42. Rosensweig R E, Heating magnetic fluid with alternating magnetic field, J. Magn. Magn.  
42  
43 Mater. 2002; 252: 370-374.  
44  
45
- 46 43. Scheffel A, Gruska M, Faivre D, Linaroudis A, Grumann P, Plitzko J M et al, An acidic protein  
47  
48 aligns magnetosomes along a filamentous structure in magnetotactic bacteria, Nature 2006;  
49  
50 440: 110-114.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 44. Alphandéry E, Chebbi I, Faure S, Treatment of cancer or tumor induced by the release of heat  
4  
5 generated by various chains of magnetosomes extracted from magnetotactic bacteria and  
6  
7 submitted to an alternative magnetic field, Patent WO2011/061259.  
8  
9  
10 45. Alphandéry E, Ding Y, Ngo A T, Wang Z L, Wu L F, Pileni M P, Assemblies of Aligned  
11  
12 Magnetotactic Bacteria and Extracted Magnetosomes: What is the Main Factor Responsible  
13  
14 for the Magnetic Anisotropy?, ACSNANO 2009; 3: 1539-1547.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




FIG. 1

Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




FIG. 2

Review Only




FIG. 3

Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




FIG. 4

For Peer Review Only